Hospitals do not automatically drug test every baby after delivery. Testing is done selectively, based on specific medical signs in the newborn or risk factors identified in the mother’s history. The exact policies vary by hospital and state, but no universal screening mandate exists in the United States. Whether your baby gets tested depends on a combination of clinical judgment, hospital protocol, and state law.
What Triggers a Newborn Drug Test
Hospitals use a set of clinical indicators to decide whether to order toxicology screening on a newborn. These typically fall into two categories: something about the baby’s condition, or something in the mother’s medical history.
On the baby’s side, testing is considered when the newborn shows unexplained symptoms like jitteriness, excessive crying, poor feeding, seizures, tremors, or difficulty breathing. These can be signs of drug exposure or withdrawal, but they can also have other causes, which is why testing helps clarify the picture.
On the mother’s side, common triggers include a disclosed or documented history of substance use, no prenatal care during the pregnancy, unexplained placental abruption (where the placenta separates from the uterine wall prematurely), or an altered mental state at the time of delivery. Guidelines from the University of Arkansas for Medical Sciences list all of these as standard medical indications for newborn testing.
Some hospitals also screen based on broader criteria like a positive maternal drug test during pregnancy or certain social history factors. Colorado’s birthing facility guidelines add that a newborn showing physical features of fetal alcohol syndrome is also an indication for testing. The specifics depend heavily on where you deliver.
How the Testing Works
Three biological samples can be used to test a newborn for drug exposure: urine, meconium (the baby’s first stool), and umbilical cord tissue. Each has different strengths.
Urine is the simplest to collect but has the shortest detection window, typically only capturing substance use in the final days before delivery. It’s often used as a quick initial screen.
Meconium testing has a much longer detection window, potentially reflecting drug exposure from roughly the second trimester onward. Meconium begins forming around 12 to 16 weeks of gestation, so substances that crossed the placenta during that time can accumulate in it. The downside is that meconium isn’t always available right away, and collection can be messy or delayed.
Umbilical cord tissue testing has become increasingly popular because it’s easy to collect immediately at birth. However, its detection window is generally shorter than meconium’s. A study published in the Journal of Pediatrics comparing the two methods in 501 newborns found that results were often different between paired samples. Overall agreement ranged from 80% to 100% depending on the substance, but when researchers accounted for chance agreement, only amphetamines and methadone had reliability scores above 75%. Cannabis detection was particularly inconsistent: cord tissue only caught 41% of the cases that meconium identified.
Both tests screen for a wide range of substances, including opioids, cocaine, amphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The sensitivity varies by drug. Cord tissue tends to be better at detecting very small amounts of opioids and amphetamines, while meconium performs better for cannabis.
What Withdrawal Looks Like in a Newborn
When a baby has been exposed to certain substances (particularly opioids) throughout pregnancy, they can develop neonatal abstinence syndrome, or NAS, after birth. This happens because the baby’s body has become physically dependent on the substance and is now adjusting to its absence.
Hospitals use a standardized scoring system to assess withdrawal severity. Nurses evaluate the baby at regular intervals, looking for specific signs: tremors in the hands or limbs (both when the baby is being handled and when left undisturbed), excessive sweating, continuous crying lasting more than five minutes despite soothing, frequent yawning, poor feeding, difficulty sleeping, increased muscle tone, skin irritation on the chin or knees from excessive movement, and muscle twitching in the face or limbs.
Each symptom gets a point value, and if the baby scores 8 or higher on two consecutive assessments, treatment is typically considered. Treatment for NAS usually involves keeping the baby comfortable in a calm, low-stimulation environment, with medication reserved for more severe cases. The process can take days to weeks depending on what the baby was exposed to and for how long.
State Laws and Reporting Requirements
Federal law under CAPTA (the Child Abuse Prevention and Treatment Act) requires states to track the number of substance-affected newborns, but it uses no identifiable patient information and does not create a clinical reporting requirement on its own. The language is intentionally broad, giving states significant flexibility in how they interpret and enforce it.
What this means in practice varies enormously. Twenty-four states plus Washington, D.C., classify substance use during pregnancy under civil child-welfare statutes, and a similar number require healthcare providers to report suspected prenatal drug use to child protective services. In some states, a positive test triggers a mandatory report. In others, the report only happens if there are additional concerns about the baby’s safety.
A positive newborn drug test does not automatically mean a child will be removed from the home. In most cases, the initial step is a referral to child protective services for an assessment, which may result in a safety plan, a referral to treatment services, or, in cases where the baby is determined to be safe, no further action. The goal of the federal framework is to connect families with support, not to criminalize mothers, though enforcement at the state and county level can feel very different from that intent.
Consent and Your Rights
Whether hospitals need your explicit consent before testing your baby depends on your state. Some states require informed consent for toxicology screening. Others allow hospitals to test without notification if there is a medical indication. In practice, many hospitals include broad consent for “necessary medical testing” in the admission paperwork you sign when you arrive in labor and delivery, which can cover toxicology screening.
If you’re concerned about testing, you can ask your hospital directly about their screening policy during a prenatal visit or at admission. You can also ask what would happen if a test came back positive. Being upfront with your medical team about any substance use during pregnancy, including prescribed medications, allows them to plan appropriately for your baby’s care and reduces the chance of a surprise result being misinterpreted.
False Positives and Prescription Medications
Initial drug screens, called immunoassays, are fast but imperfect. They work by detecting chemical structures similar to the target drug, which means certain prescription medications or even over-the-counter products can trigger a false positive. Poppy seed consumption is a well-known example for opioid screens. Some antidepressants, antihistamines, and blood pressure medications have also been associated with false results on initial screens.
For this reason, any positive immunoassay result should be confirmed with a more precise method called mass spectrometry, which can distinguish between the actual drug and a look-alike compound. If you were taking a prescribed medication during pregnancy, let your medical team know so they can interpret any results in context. A confirmed positive for a substance you were legally prescribed, like buprenorphine for opioid use disorder, is handled very differently than a positive for an illicit drug.